195 filings
Page 2 of 10
424B5
6ipzwgmjy1kb65wyo9
23 Mar 23
Prospectus supplement for primary offering
4:50pm
6-K
l55dg59
23 Mar 23
Affimed Reports 2022 Financial Results and Operational Progress
4:13pm
6-K
yiz4ltqvtjargk0w
9 Jan 23
Affimed Reports on Corporate Progress and Provides
6:45am
6-K
h6l9u8
12 Dec 22
Affimed Provides Updated Clinical Data from Phase 1/2 Study of
8:15am
6-K
12kap6wt an
15 Nov 22
Current report (foreign)
6:42am
6-K
gq1zklpvg e5xyeu
3 Nov 22
Affimed and Artiva Biotherapeutics Announce Partnership to Advance
9:23am
6-K
pxee rpqq
11 Aug 22
Current report (foreign)
6:31am
6-K
1mbg3 kw26f32
23 Jun 22
Current report (foreign)
7:28am
6-K
yver uao1eav
1 Jun 22
Current report (foreign)
6:53am
6-K
d20fij id
24 May 22
Affimed Announces Annual General Meeting of Shareholders
6:40am
6-K
7w0u72al
18 Apr 22
Current report (foreign)
4:06pm
424B5
4op3bs m9vx88tj16
14 Apr 22
Prospectus supplement for primary offering
4:17pm
424B5
fhe5 941uj
12 Apr 22
Prospectus supplement for primary offering
4:11pm
6-K
izywrs3q ltc
11 Apr 22
Affimed Presents Findings from the Dose-escalation Phase of the First-in-human
6:32am
EFFECT
tuc0s60bm tjz
7 Apr 22
Notice of effectiveness
12:15am
POS AM
d8332vupz8puz1 p9nos
31 Mar 22
Prospectus update (post-effective amendment)
4:37pm
6-K
yfocz
31 Mar 22
Affimed Reports 2021 Financial Results and Highlights Recent Operational Progress
7:17am
POSASR
6dnpoh
31 Mar 22
Automatic shelf registration (post-effective amendment)
7:10am